The Claim
In obese men with hypogonadism receiving GLP-1/GIP therapy, testosterone replacement increases IIEF sexual function scores by 3.8–4.6 points, while absence of testosterone replacement is associated with a decline of 2.1 points in IIEF scores.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese men with low testosterone who are taking GLP-1/GIP medication, adding testosterone replacement raises sexual function scores by 3.8 to 4.6 points, while not adding testosterone results in a drop of 2.1 points in those scores.
See the scientific wording
In obese men with hypogonadism on GLP-1/GIP therapy, testosterone replacement improves sexual function (IIEF score) by 3.8–4.6 points, while without testosterone, sexual function declines by 2.1 points, indicating a clinically meaningful benefit on quality of life.
Testosterone activates receptors in muscle and nerve cells, which boosts protein building and strengthens nerve signals to muscles. This improves physical strength and energy, which directly supports sexual function. Without testosterone, the body breaks down muscle and weakens nerve signals, leading to reduced sexual performance.
What the research says
1 studyIn obese men with low testosterone who are taking weight-loss drugs, those who also got testosterone therapy felt better sexually, while those who didn’t get testosterone felt worse. The study proved this difference clearly.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.